This approach may also open avenues for systematically exploring therapy-induced tumor evolution and determining eligibility for trials based on cfDNA-derived CNVs, such as MYC(N) amplifications required for enrollment into the INFORM2 NivEnt trial [67]. This evidence concerns the gene MYC and neoplasm.